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Abstract 
Background: Antimicrobial resistance is a global public health concern contributing to increased morbidity and 
mortality particularly in low-income countries. Studies on commensal bacteria are important as they reflect the state 
of antimicrobial susceptibility patterns in populations. However, susceptibility data on potentially pathogenic com-
mensal bacteria from individuals in communities are still limited. The aim of this cross-sectional study was to deter-
mine the susceptibility profiles of Escherichia coli and Klebsiella species isolated from clients attending outpatient 
clinics in Kampala (urban district) and two rural districts of Uganda, Kayunga and Mpigi. Factors associated with such 
carriage are also reported.
Results: A total of 1448 participants were recruited into the study with 985 yielding organisms of interest from stool 
or urine samples (one per client). Most growth occurred from stool samples (636/985, 87 %), of which 620/636 (97 %) 
grew E. coli while 16 (3 %) were Klebsiella pneumoniae. Growth from urine was 349/985 (35 %) of which 310/349 (89 %) 
were E. coli while 39 (11 %) K. pneumoniae. High rates of antimicrobial resistance were detected among E. coli and 
Klebsiella isolates combined: sulphamethoxazole/trimethoprim 70 %, amoxicillin/clavulanate 36 %, chloramphenicol 
20 %, ciprofloxacin 11 %, gentamicin 11 %, nitrofurantoin 4 %, ceftriaxone 3 %, piperacillin/tazobactam 27 %, cefoxitin 
22 %, and cefepime 15 %. Multidrug resistance was noted in 33 % of the isolates. None of the isolates were resistant to 
imipenem. Overall, isolates from Kampala were more resistant to antimicrobials. Across the three districts combined, 
isolates producing beta-lactamase enzymes extended spectrum β-lactamase-(ESBL) and AmpC comprised 5.3 and 
13.2 %, respectively. Further, medical procedures involving inoculation were independent risk factors [aOR 50.76 (1.80, 
1432.90)] while residing in a rural district and use of sulphamethoxazole/trimethoprim 3 months prior to visiting the 
outpatient clinics were protective against carriage of multidrug resistant isolates. Furthermore, use of gentamicin 
was protective against AmpC producing isolates while clients attending HIV/AIDs clinics were less likely to carry such 
isolates. No factor was independently associated with carriage of ESBL-producing isolates.
Conclusion: Antimicrobial resistance is prevalent among E. coli and K. pneumoniae carried in the gut of clients 
attending outpatient clinics in Kampala and two rural districts in Uganda. This could complicate treatment options for 
community-acquired infections caused by the Enterobacteriaceae.
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Background
Antimicrobial resistance has become an issue of public 
health concern [1]; it is a major factor contributing to 
mortality and morbidity in settings with limited diagnos-
tic facilities and treatment options. Fecal Escherichia coli 
is as an indicator of spread of acquired resistance-encod-
ing genes in the community [2–4]. Klebsiella species on 
the other hand are opportunistic pathogens that play 
significant roles in hospital-acquired infections. Studies 
have shown that Klebsiella species have diverse resistance 
patterns to β-lactam agents. Although they are compo-
nents of the normal flora, E. coli and Klebsiella species 
are considered potential causes of both community and 
hospital acquired infections [5].
Studies on commensal bacteria provide a more accu-
rate reflection of the overall antimicrobial resistance 
burden in the population than data based on patho-
genic isolates. In fact, studies on commensal bacteria in 
developing countries have shown high resistance rates to 
diverse antimicrobial agents [6]. In addition, drug resist-
ance surveillance has revealed that asymptomatic carri-
ers in the community are often colonized with resistant 
bacteria that subsequently lead to infection [7, 8]. Such 
studies are useful in the monitoring and understanding 
resistance mediated selection in populations [9].
In Uganda, antibiotics are readily available over the 
counter in community pharmacies [10], which portends 
significant rates of resistance among flora circulating 
within the community. In addition, inappropriate use of 
antimicrobials by pastoralists for animal diseases and the 
carriage of drug resistant potentially nosocomial bacteria 
in the livestock gut has been documented [11, 12]. Cur-
rently, most available data focuses on susceptibility of 
isolates from established infections without much atten-
tion on commensal isolates, particularly the Enterobac-
teriaceae [11, 12]. Furthermore, drug resistance is also 
prevalent in hospital settings in Uganda [13]. Moreover, 
the health care seeking behaviors in the community may 
vary depending on socioeconomic status of individu-
als involved [14]. Yet, information on resistance surveil-
lance particularly for isolates from community settings 
is scarce as surveillance mainly focuses on susceptibility 
of isolates collected from clinical specimens in hospitals. 
The aim of this study was to characterize the antimicro-
bial susceptibility profiles of E. coli and Klebsiella species 
isolated as flora from faeces and urine of clients attending 
outpatient clinics in Uganda, and to investigate the fac-
tors associated with carriage of drug resistant isolates.
Methods
Study design
This was a cross-sectional study in which antimicro-
bial susceptibility testing was performed for E. coli and 
Klebsiella species isolated from stool or urine of asymp-
tomatic clients attending outpatient clinics.
Study sites and setting
Uganda comprises 111 administrative districts and one 
city, Kampala. Districts are further subdivided into coun-
ties and sub-counties. Uganda has three types of health-
care facilities; ‘Public’, ‘Private Not for Profit’ (PNFP) and 
‘Private for Profit’. The Public and PNFP facilities are the 
most visited by Ugandans serving about 70 % of the pop-
ulation [15]. The levels of healthcare together with proto-
cols guiding treatment are described elsewhere [10].
There were two study sites categorized ‘urban’ or ‘rural’ 
with varied distance and district human poverty index 
(HPI) [16]. The study districts were purposively selected 
with the assumption that urban areas favor increased 
exposure to antimicrobials and transmission of bacteria 
is less in areas of low humidity compared to those of high 
humidity [17]. The selected urban district and one of the 
rural districts are of wet tropical climate [18], while the 
other rural district is of wet and dry tropical climate. The 
urban site was Kampala district, which is the capital and 
largest city in Uganda with a HPI of 20.5. The rural sites 
included two districts in central Uganda namely, Kayunga 
74 km and Mpigi 29.7 km from Kampala with HPI of 30.8 
and 27.5, respectively, Fig.  1. The study was conducted 
among individuals attending outpatient clinics at 44 Pub-
lic and PNFP hospitals or health centres including 16 in 
Kampala, 9 in Kayunga, and 19 in Mpigi.
Study population and sample size estimation
The number of clients recruited from each facility was 
proportional to the contribution of the facility to the out-
patient clinic attendance in the 3  months of April, May 
and June of the year 2006. The study was conducted in 
the second quarter of 2007 as a pilot in the urban district 
and the second quarter of 2008 for the two rural districts. 
All clients attending clinics were eligible to participate 
and the exclusion criteria was failure to provide either a 
stool or urine sample.
In Uganda no data exists on antimicrobial resistance 
among E. coli and/or Klebsiella pneumoniae in well-
defined community infections. As such, the sample size 
was computed based on the prevalence of K. pneumo-
niae carriage in urine which has been observed to be 
about 19.6 % among clinical samples at clinical microbi-
ology laboratory, College of Health Sciences, Makerere 
University (unpublished observations). The formula 
N = [(Z(α/2))2 *P *(1 − p)]/d2 = 242 where; Z = 1.96 (the 
standard normal deviation at 95  % CI), P  =  estimated 
prevalence of the problem under study (P  =  0.196), 
d  =  margin of error (precision) of prevalence esti-
mate at 5  % (0.05), α =  level of significance at 5  % and 
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n  =  required sample size was used. Primary sampling 
clusters were used to recruit individuals and thus, using 
a design effect of 2.0, the sample size under cluster sam-
pling was 484 per district and 1452 for the three districts 
combined.
Selection of health care facilities and participants
In each of the three districts multistage sampling was done 
based on the average clinic attendance for each district to 
ensure a sample size of 484, given an observed frequency 
of Klebsiella species in 19.6  % of urine specimens and a 
design effect of 2, Fig. 2. Thirty clusters of 16–20 partici-
pants were selected from each district using the prob-
ability proportion to size sampling, which ensured all 
individuals in the target population had an equal chance of 
being selected. Two busy days of a week were purposively 
selected to visit each health care facility. When the number 
exceeded 20, systematic sampling was carried out.
Data collection
A standardized interviewer administered questionnaire 
(Additional file 1: Figure S1) was used to collect data on 
socio-demographics (age, sex, and residence), heath care 
unit, and reason for visit and history of use of antimicro-
bial agents, history of admission and history of medical 
procedures in the previous 3 months.
Sample collection
Participants were instructed to provide a stool or a 
urine sample if they were unable to provide stool. The 
Fig. 1 Study sites. The map was obtained from the URL to this figure is https://www.commons.wikimedia.org/wiki/File:Uganda_sub-counties.png, 
but slightly modified to emphasize the study sites
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specimens were collected in sterile containers with screw 
caps. Samples from rural districts were stored at 4  °C 
for one to 3 days prior to transportation by road in cool 
boxes while those from Kampala were transported to the 
laboratory on the day of collection.
Cultures
Isolation of E. coli and Klebsiella species and the antimi-
crobial susceptibility testing were performed at the Clini-
cal Microbiology Laboratory, College of Health Sciences, 
Makerere University. The laboratory participates in the 
College of American Pathologist bacteriology external 
quality assurance scheme (CAP no. 7225593).
Samples were streaked onto MacConkey agar and 
incubated for 18–24 h at 37 °C in ambient air. In case of 
stool, specimens were first emulsified in sterile normal 
saline before inoculation of the MacConkey plates. Lac-
tose fermenting isolates, from the fourth or third streak 
area with colonial morphologies suggestive of E. coli and 
Klebsiella species were subjected to an oxidase test, and 
when negative, they were cultured for 18–24 h on the fol-
lowing media: triple sugar and iron (TSI) agar, Simmon’s 
citrate agar, and sulphide-indole-motility (SIM) media 
for identification. Following identification, E. coli and 
Klebsiella isolates with inconclusive identification were 
confirmed with the API 20E system (BioMerieux Marcy 
1’Etoile, France).
Antimicrobial susceptibility testing
Drug susceptibility testing (DST) was performed with the 
disc diffusion method on Mueller Hinton Agar (MHA) 
(Biolab, Hungary) plates as recommended by the clini-
cal laboratory standards institute (CSLI). Three colonies 
were emulsified into sterile saline and the turbidity of 
the suspension adjusted to the 0.5 McFarland standard. 
The antimicrobial disks (Biolab, Hungary) used included 
ampicillin (10  µg), amoxicillin/clavulanate (20/10  µg), 
cefuroxime (30  µg), ceftriaxone (30  µg), cefotaxime 
(30  µg), ceftazidime (30  µg), meropenem (30  µg), tri-
methoprim/sulfamethoxazole (1.25/23.75  µg), chloram-
phenicol (30 µg), gentamicin (10 µg), ciprofloxacin (5 µg), 
nitrofurantoin (300  µg), cefepime (30  µg), piperacillin/
tazobactam (100/10 µg) and cefoxitin (30 µg).
Escherichia coli ATCC 25992/ATCC 35218, Staphy-
lococcus aureus ATCC 25923, and Pseudomonas aer-
uginosa ATCC 27853 were used to quality control the 
susceptibility testing procedures in line with CLSI 
guidelines.
For isolates resistant to second or third generation 
cephalosporins, minimum inhibitory concentrations 
(MICs) were performed by E-test (AB BIODISK Solna, 
Sweden) according to the manufacturer’s instructions 
and these were confirmed using the Vitek 2 identifica-
tion and susceptibility system (Biometric, Marcy I’Etoile, 
France). The results were interpreted according to CLSI 
guidelines [19].
Detection of extended spectrum β‑lactamase production
Detection of extended spectrum β-lactamases (ESBLs) 
was performed using the double disc synergy test (DDST) 
using amoxicillin/clavulanate, ceftazidime, ceftriaxone, 
aztreonam, and cefotaxime as previously described [20, 
21]. E-test strips (containing cefotaxime/ceftotaxime-
clavulanate, ceftazidime/ceftazidime-clavulanate and 
cefepime/cefepime-clavulanate) (AB BIODISC, Solna, 
Sweden) were used. K. pneumoniae 70,063 was used to 
control ESBL detection. The E test ESBL strip (AB Bio-
disk, Solna, Sweden) carries two gradients: on one end, 
ceftazidime or cefotaxime; and on the opposite end, cef-
tazidime or cefotaxime plus clavulanic acid. MIC were 
interpreted as the point of intersection of the inhibition 
ellipse with the E test strip edge. A ratio of ceftazidime or 
cefotaxime MIC to ceftazidime or cefotaxime-clavulanic 
acid MIC equal to or greater than eight indicated the 
presence of ESBL (manufacturer’s instructions) [22].
Phenotypic detection of AmpC enzymes
Phenotypic detection of AmpC β-lactamase production 
was performed on isolates with reduced cefoxitin diam-
eters (≤17 mm). These were sub-cultured on MHA con-
taining 8 μg/ml of cefoxitin agar (USP reference standard, 
Fig. 2 Study flow chart
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Rockville) and screened with E-test strips (cefotetan/
cefotetan-cloxacillin, CN/CNI AB BIODISC, Solna, Swe-
den). A ratio of  ≥8, deformation of the ellipse, or the 
presence of a phantom zone were interpreted as positive 
for AmpC production [23].
Data analysis
Questionnaire responses and DST data were checked 
for completeness. Data was double entered for valida-
tion using EPIDATA software, cleaned and exported 
to STATA (v10) for analysis. Data were analyzed using 
descriptive statistics, frequencies and bivariate analyses 
(cross-tabulations). Associations were tested using Pear-
son’s Chi square. A significant level was set at p = 0.05. 
Odds ratios (OR) were determined between socio-demo-
graphic variables, health facility level, district, reason 
for visit, prior use of antimicrobial, history of hospital 
admission and medical procedures 3  months prior to 
visits, with the following outcomes; (1) resistance to one 
antibiotic, (2) resistance to three different classes of anti-
microbial agents -multi-drug resistance (MDR), (3) ESBL 
phenotype, (4) AmpC phenotype.
Variables with p < 0.15 were entered into multivariate 
logistic regression models with backward elimination. To 
control for the effect of clustering, regression with robust 
standard errors was used. Independent variables used 
were; sex (male versus female), health center level, health 
sub-district and district, history of admission, procedures 
and antibiotic use recalled by client and from health 
record, in the previous 3 months.
Differences between proportions of resistant isolates 
were determined to compare variation within districts 
using MDR as surrogate marker. MDR was determined 
based on categories and drugs used to determine sus-
ceptibility among the Enterobacteriaceae [24]. The 
categories included: aminoglycosides (gentamicin); 
anti-pseudomonal penicillin/β-lactamase inhibitor 
(piperacillin/tazobactam); carbapenem (meropenem); 
non-extended spectrum cephalosporins (cefuroxime); 
extended spectrum cephalosporin (ceftriaxone, ceftazi-
dime, cefotaxime, cefepime); cephamycins (cefoxitin); 
fluoroquinolone (ciprofloxacin); folate pathway inhibitors 
(sulphamethoxazole/trimethoprim); penicillins (ampicil-
lin); and phenicols (chloramphenicol). These 11 antimi-
crobial agents represented 11 of the 16 recommended 
categories however, second and third generation cepha-
losporins were considered as oxyminocephalosporins.
Results
A total of 1448 participants were recruited; 474 (33  %) 
Kampala, 508 (35  %) Kayunga, and 466 (32  %) Mpigi. 
Females were 913 (63.3 %) while men were 529 (36.7 %) 
and the difference was statistically significant (p = 0.005). 
The mean age of the participants was 24.8  years (SD 
17.5) (Table  1); 802 (55.7  %) of them belonged to the 
15–44 year age group. Participants provided 730 and 718 
stool and urine samples, respectively, which were cul-
tured for identification of E. coli and Klebsiella isolates.
Socio‑demographic factors of participants
Five hundred and thirty-five participants visited the clin-
ics for general conditions and these comprised headache 
and fever (422, 28.49  %); follow-up review (85, 5.74  %); 
antenatal care 20 (1.35  %); and cardiovascular diseases 
(15, 1.01 %). Other reasons for visits included infections 
(731, 52.7  %), such as respiratory tract infections (312, 
21.07 %); gastro-intestinal (309, 20.86 %); genital urinary 
infections (125, 8.44 %); skin infections (64, 4.32 %); and 
attending HIV/AIDS clinics (122, 8.71  %). Use of anti-
microbials 3  months prior to the study was high (1093, 
75.5  %); septrin (774, 70.6  %); penicillins (369, 33.9  %), 
ciprofloxacin (130, 11.9  %); and gentamicin (45, 4.1  %), 
Table  1. One hundred and twenty-five (125, 8.7  %) par-
ticipants had been admitted to hospital 3  months prior 
to the clinic visit while 130 (8.9  %) underwent medical 
procedures, of which 17 (13.1  %) involved only contact 
(such as radiological investigations) while 88 (67.7 %) had 
investigations like taking blood for malaria, injections 
and infusion (inoculation), and 25 (19.2  %) had minor 
or major surgery. Overall, there was significant variation 
among the parameters related with resistance across the 
three districts, Table 1.
Prevalence of E. coli and Klebsiella species
Of the 1448 participants, growth of E. coli or K. pneu-
moniae was obtained from 985 samples and signifi-
cant variation was observed across the three districts; 
274 Kampala, 406 Kayunga, and 305 Mpigi (p  <  0.001). 
Growth from stool occurred in 636 (87  %) samples of 
which 620 (97 %) were E. coli and 16 (3 %) were K. pneu-
moniae. Growth from urine occurred in 349 (49  %) 
samples of which 310 (89 %) were E. coli and 39 (11 %) 
K. pneumoniae; none of the urine samples had growth 
of ≥104 colony forming units (CFU) implying there was 
no infection-related growth. Forty-one samples grew 
both E. coli and K. pneumoniae; where both grew, E. coli 
was considered as it is the commonest cause of commu-
nity infections. Overall 930 (94.4 %) E. coli and 55 (5.6 %) 
K. pneumoniae isolates were isolated and studied.
Susceptibility profiles
Overall, two hundred and seven (207, 21 %) isolates were 
susceptible to all antimicrobial agents tested;
1. β-lactam agents; 617 (67  %) E. coli isolates were 
resistant to ampicillin (Klebsiella were omitted as 
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they are inherently resistant to ampicillin). Resist-
ance to other drugs was (for both Klebsiella and E. 
coli); 145 (14 %) cefuroxime, 29 (3 %) ceftriaxone, and 
359 (36  %) amoxicillin/clavulanate. Further analysis 
revealed resistance in 263 (27 %) isolates for pipera-
cillin/tazobactam, 213 (22 %) cefoxitin and 152 (15 %) 
cefepime, Table 2. Although none of the isolates was 
resistant to meropenem, zone diameters of ≤ 25 mm 
were noted in 167 (17 %) of the isolates a finding that 
necessitates screening for carbapenamase activity.
2. Other antimicrobial agents. High resistance against 
sulphamethoxazole/trimethoprim (698, 69  %), chlo-
ramphenicol (19  %, 195), ciprofloxacin (107, 11  %), 
gentamicin (106, 11 %), and nitrofurantoin (40, 4 %) 
was detected. Overall, resistance did not vary by 
gender except that isolates from females 123/167 
(74 %) were more likely to have reduced susceptibil-
ity (inhibition zone diameter  ≤25) to carbapenems 
(p < 0.023).
3. MDR was noted in 356 (36.1  %) isolates and there 
was significant variation across districts (p < 0.001). 
Three hundred and twenty-three E. coli isolates 
(323/930, 34.7  %) and 33 (33/55, 60  %) Klebsiella 
isolates were MDR and the finding was statistically 
significant (p < 0.001). The highest MDR prevalence 
was observed in Kampala, an urban district. MDR 
phenotype also varied by health sub-districts (HSD) 
ranging from 9/46 (19.6 %) in rural to 26/33 (79 %) in 
urban. Further, the MDR phenotype was detected in 
all health care facilities in Kayunga (9) and Kampala 
(16), and was not detected in 4 of the 19 health care 
facilities in Mpigi. Among the Ampicillin resistant 
Table 1 Characteristics of participants attending OPDs in the three study sites
HCIII health center III, HCIV health center IV, ISS immunosuppressive syndrome
Kampala n (%) Kayunga n (%) Mpigi n (%) Total n (%) p value
Sex
 Female 324 (68.8) 297 (58.8) 292 (62.7) 913 (63.3)
 Male 147 (31.2) 208 (41.2) 174 (37.3) 529 (36.7) 0.005
 Age—years (SD) 23.5 (15.4) 22.5 (16.5) 28.8 (19.7) 24.8 (17.5)
Age (years)—groups
 0–14 121 (25.7) 196 (38.9) 126 (27.0) 443(30.7)
 15–44 310 (65.8) 249 (49.4) 243 (52.2) 802 (55.7)
 45+ 40 (8.5) 59 (11.7) 97 (20.8) 196 (13.6) <0.001
Health centre level
 National referral hospital 197 (41.6) 0 (0.0) 0 (0.0) 197 (13.6)
 General hospital 152 (32.1) 114 (22.4) 158 (33.9) 424 (29.3)
 HCIV 17 (3.6) 150 (29.5) 50 (10.7) 217 (15.0)
 HCIII 108 (22.8) 244 (48.0) 258 (55.4) 610 (42.1) <0.001
Specimen
 Stool 167 (35.2) 469 (92.3) 94 (20.2) 730 (50.4)
 Urine 307 (64.8) 39 (7.7) 372 (79.8) 718 (49.6) <0.001
Prescription
 Yes 319 (67.3) 383 (75.4) 391 (84.1) 1093 (75.5)
 No 155 (32.7) 125 (24.6) 74 (15.9) 354 (24.5) <0.001
Reason for visit
 ISS 24 (5.1) 55 (11.7) 43 (9.6) 122 (8.8)
 Infection 268 (57.3) 227 (48.2) 236 (52.6) 731 (52.7)
 General 176 (37.6) 189 (40.1) 170 (37.9) 535 (38.5) 0.003
History of admission
 Yes 41 (8.7) 9 (1.8) 75 (16.5) 125 (8.7)
 No 433 (91.4) 494 (98.2) 379 (83.5) 1306 (91.3) <0.001
History of medical procedures
 Contact 17 (30.4) 0 (0.0) 0 (0.0) 17 (13.1)
 Inoculation 34 (60.7) 17 (89.5) 37 (67.3) 88 (67.7)
 Surgery 5 (8.9) 2 (10.5) 18 (32.7) 25 (19.2) <0.001
Page 7 of 14Najjuka et al. BMC Res Notes  (2016) 9:235 
isolates, 32 (3 %) were resistant to nitrofurantoin, 94 
(9 %) gentamicin, 100 (10 %) ciprofloxacin, 192 (19 %) 
chloramphenicol and 592 (60 %) septrin. In addition, 
there was high resistance among the isolates to mul-
tiple drug combinations, Table 3.
Prevalence of ESBL‑producing isolates
Overall, 209 bacterial isolates from 40 health care centers 
qualified for AmpC screening (based on cefoxitin resist-
ance) while 63 isolates from 23 health centers qualified for 
ESBL-screening (based on CLSI guidelines). AmpC and 
ESBL-producing isolates were higher in Kampala [ESBL; 
35/274 (12.8  %), AmpC; 65/274 (23.7  %)] compared to 
Kayunga [ESBL 7/406 (1.7 %), AmpC; 27/406 (6.7 %)] and 
Mpigi [10/305 (3.3 %), AmpC; 37/305 (12.1 %)]. However, 
among isolates that qualified for screening for ESBLs, 
there was no significant difference in the distribution of 
the enzymes across the three districts i.e. for ESBLs in 35 
(83.3 %), 7 (77.8 %) and 10 (83.3 %) isolates (p = 0.886) 
and AmpC in 65 (53.3 %), 27 (46.6 %) and 37 (55.2 %) iso-
lates (p = 0.505); for both enzymes in Kampala, Kayunga 
and Mpigi, respectively.
AmpC enzymes were detected in 61  % (116/191) and 
72  % (13/18) E. coli and Klebsiella, respectively (χ2 (1) 
4.9527, p = 0.026). ESBLs were detected in 81 % (42/52) 
E. coli and 100  % (10/10) of the screened Klebsiella 
Table 2 Antimicrobial resistance profiles of E. coli and Klebsiella pneumoniae in the three districts
a Only Escherichia coli
b Only amoxicillin clavulanic acid resistant isolates tested
Antimicrobial Districts p value (variation 
across the districts)
Kampala n/N (%) Kayunga n/N (%) Mpigi n/N (%) Total n/N (%)
Ampicillina 224/258 (86.8) 218/396 (55.1) 175/275 (63.9) 617/928 (66.5) <0.001
Amoxicillin-clavulanate 184/274 (67.2) 80/406 (19.7) 88/304 (29.0) 352/984 (35.8) <0.001
Cefuroxime 43/273 (15.8) 77/405 (19.0) 22/304 (7.2) 142/982 (14.5) <0.001
Ceftriaxone 16/274 (5.8) 2/406 (0.5) 10/303 (3.3) 28/983 (2.9) <0.001
Cefotaxime 14/273 (5.1) 2/406 (0.5) 6/302 (2.0) 22/981 (2.2) <0.001
Ceftazidime 15/273 (5.5) 2/406 (0.5) 8/304 (2.6) 25/983 (2.5) <0.001
Cefepimeb 93/178 (52.3) 26/76 (34.2) 29/91 (31.9) 148/345 (42.9) 0.001
Ciprofloxacin 73/274 (26.6) 15/405 (3.7) 17/304 (5.6) 105/983 (10.7) <0.001
Sulfamethoxazole-trimethoprim 234/272 (86.0) 262/405 (64.7) 189/304 (62.2) 685/981 (69.8) <0.001
Gentamicin 68/273 (24.9) 19/406 (4.7) 18/303 (5.9) 105/982 (10.7) <0.001
Nitrofurantoin 23/270 (8.5) 4/403 (1.0) 8/304 (2.6) 35/977 (3.6) <0.001
Chloramphenicol 83/273 (30.4) 54/405 (13.3) 56/301 (18.6) 193/979 (19.7) <0.001
Cefoxitinb 106/181 (58.6) 40/78 (51.3) 63/88 (71.6) 209/(60.2) 0.023
Piperacillin-tazobactumb 126/173 (72.8) 64/79 (81.0) 67/93 (72.0) 257/345 (74.5) 0.315
Meropenem 0/273 (0.0) 0/403 (0.0) 0/300 (0.0) 0/976 (0.0) –
Table 3 Frequency and patterns of resistance phenotypes among isolates from the study sites
Number of drug 
classes
Drug combination Number of isolates resistant 
to drug combination
3 Ampicillin + sulphamethoxazole-trimethoprim + chloramphenicol 183
Ampicillin + sulphamethoxazole-trimethoprim + ciprofloxacin 92
Ampicillin + sulphamethoxazole-trimethoprim + gentamicin 88
Ampicillin + sulphamethoxazole-trimethoprim + nitrofurantoin 22
4 Ampicillin + sulphamethoxazole-trimethoprim + quinolone + aminoglycoside 57
5 Ampicillin + sulphamethoxazole-trimethoprim + quinolone + aminoglycoside + nitrofurantoin 9
6 Ampicillin + sulphamethoxazole-trimethoprim + quinolone + aminoglycoside + nitrofuran-
toin + chloramphenicol
6
7 Ampicillin + sulphamethoxazole-trimethoprim + quinolone + Aminoglycoside + nitrofuran-
toin + chloramphenicol + oxyminocephalosporins
5
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isolates. The coexistence of ESBLs and AmpC enzymes 
was detected in 28.8 % (15/52) of the isolates. The cefoxi-
tin inhibition zone diameters of  ≤13  mm were signifi-
cantly associated with presence of AmpC enzymes in 
both E. coli and Klebsiella isolates (p < 0.038) but it was 
not the case for ESBLs when reduced zone diameters rec-
ommended for ESBL screen (CLSI) were used (p = 1.00).
The overall prevalence of AmpC phenotype was 13  % 
(129/985) for the three districts. Whereas 97 of the 182 
MDR screened had AmpC enzyme, this was not statis-
tically significant [χ2 (1)  =  0.0253, p  =  0.874]. Isolates 
bearing AmpC β-lactamase were sensitive to gentamicin 
96/129 (74 %) [χ2 (1) 4.766, p < 0.029] while 74 % (90/122) 
of them were resistant to piperacillin/tazobactam much 
as this association was not significant [χ2 (1) 0.766, 
p = 0.381].
The prevalence of the ESBL phenotype was 5.3  % 
(52/985). Among isolates bearing ESBLs β-lactamase and 
were resistant to amoxicillin/clavulanate, 86  % (32/37) 
were also resistant to piperacillin/tazobactam [χ2 (1) 
0.087, p = 0.767].
Univariate analysis and logistic regression model
On univariate analysis, significant risk factors for car-
riage of ESBLs among outpatient clinic attendees were 
Health center level (p =  0.037) and use of antibacterial 
agent in the last 3 months prior to clinic visit (p = 0.023), 
Additional file 2: Table S1. In addition to these the health 
sub-districts with less than 100 participants with growth 
(p = 0.079) and use of septrin (p = 0.088) were the vari-
ables included in the logistic regression model. Using 
backward stepwise procedure, no independent risk factor 
for carriage of ESBL enzymes was identified. However, 
without controlling (for other factors), use of antimicro-
bials 3 months prior to clinic visit was found to be asso-
ciated with carriage of ESBL cOR 4.47 (95  % CI 1.15, 
17.44), Table 4.
Significant risk factors at univariate analysis for car-
riage of AmpC enzymes were reason for coming to clinic 
(p  =  0.003), history of admission (p  =  0.023) and his-
tory of medical procedures (p = 0.044), Additional file 2: 
Table S1. These variables, together with sex (p = 0.132) 
and use of gentamicin (p = 0.100) were included in the 
model. Following backward stepwise procedure, visiting 
the outpatient clinic for reasons other than infection or 
HIV/AIDs care [aOR 3.56 (95 % CI 1.08, 11.77)] was an 
independent risk factor for carriage of AmpC produc-
ing E. coli and K. pneumoniae while use of gentamicin 
was independent of such carriage [aOR 0.17 (95  % CI 
0.03–0.95]. However, without controlling for other fac-
tors, history of admission was found to be associated 
with carriage of AmpC [cOR 2.76 (95 % CI 1.12, 6.84)], 
Table 4.
MDR isolates were prevalent across the three districts 
and in the univariate analysis the significant factors for 
carriage of MDR isolates were age group (p  =  0.004), 
health center level (p  <  0.001), health sub-district 
(p  <  0.001), district of residence (p  <  0.001), health 
sub-district (group of  <100 participants with growth 
(p < 0.001), Additional file 2: Table S1, and use of septrin 
(p  <  0.001), Additional file  2: Table S1 (Additional file 
3: Table S2). In multivariate analysis four variables; age 
group, health center level, district of residence, and use 
of septrin together with history of medical procedures 
(p  =  0.075), use of antimicrobial agents (p  =  0.122); 
including use of ciprofloxacin (p  =  0.071) and were 
included in the model. Using backward stepwise proce-
dure, having had medical procedures involving inocula-
tion in the last 3 months prior to visiting health facility 
was independent risk factor for carriage of MDR isolates 
[aOR 50.76 (95  % CI 1.80–1432.90)]. However, without 
controlling for other factors when compared to resi-
dence in Kampala, residing in Kayunga and Mpigi was 
protective by 83 % (95 % CI 0.11–0.26) and 80 % (95 % 
CI 0.13, 0.32), respectively and septrin use was protec-
tive by 47 % (95 % CI 0.40, 0.71) of carriage of MDR E. 
coli or K. pneumoniae. Furthermore, the age group 15–44 
was 1.65 times more likely to have MDR isolates (95 % CI 
1.22, 2.23) compared to participants less than 15  years 
and HSD with less than 100 cases were 1.75 times more 
likely to have such isolates (0.5  % CI 1.33–2.29). Also, 
attending lower hospitals was protective from carriage of 
MDR isolates when compared to National referral hospi-
tals [cOR 0.32 (95 % CI 0.20, 0.52)] for general hospitals, 
HCIV [cOR 0.27 (95  % CI 0.16, 0.46)] and HCIII [cOR 
0.21 (95 % CI 0.13, 0.33)], Table 4.
Discussion
We have reported the prevalence and susceptibility pat-
terns of E. coli and K. pneumoniae isolated from the 
intestinal and urinary tracts of individuals attending 
urban and rural outpatient clinics in Uganda. In order to 
study susceptibility of flora among outpatient department 
(OPD) clients for the first time, the study was conducted 
in two phases a pilot study that took place between May 
and June of 2007, and involved generating sampling 
frame, seeking permission and recruitment took place 
in Kampala district. The aim was to test the recruitment 
strategy and sample collection, transportation and analy-
sis. The experience from the pilot study was then used for 
study activities in the two rural districts.
The findings in this study reveal high rates of resistance 
to commonly used antibiotics such as ampicillin and sep-
trin and relatively lower resistance rates to amoxicillin/
clavulanate, chloramphenicol, ciprofloxacin, gentamicin, 
nitrofurantoin and ceftriaxone. These findings are similar 
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to those from neighboring Kenya [25]. The high levels 
of resistance to piperacillin/tazobactam and cefoxitin 
among the amoxicillin/clavulanate resistant isolates 
found were associated with AmpC enzymes. Despite 
the low resistance to third generation cephalosporins, 
ESBLs were detected in 5.3  % isolates most of which 
were MDR with co-resistance to ciprofloxacin, septrin 
and gentamicin. However, the MDR rates in our study 
was lower than that of fecal carriage among outpatient 
department volunteers in Cameroon [26]. This study also 
found that E. coli is the species most commonly isolated 
among ESBL producers [26]. The prevalence of ESBLs in 
Table 4 Unadjusted and adjusted Odds ratios (OR) of ESBLs, AmpC and MDR by participants characteristics
The analysis for association of predictor and outcome (p ≤ 0.15)
NR national referral, GH General hospital, HCIV health center 4, HCIII health center III, HSD health sub-district, cOR crude odds ratio, aOR adjusted odds ratio, ISS 
immune suppression syndrome (HIV/AIDS)
a Significant association
Characteristics ESBL AmpC MDR
cOR (95 % CI) aOR (95 % CI) cOR (95 % CI) aOR (95 % CI) cOR (95 % CI) aOR (95 % CI)
Age
 0–14 1.0 1.0
 15–44 1.65 (1.22, 2.23)a 6.49 (0.91, 46.16)
 45+ 1.38 (0.90, 2.12) 1.89 (0.21, 16.75)
Sex
 Female 1.0 1.0
 Male 1.52 (0.88, 2.63) 1.51 (0.76, 2.97)
HC level
 NR 1.0 1.0 1.0 1.0
 GH 1.65 (0.35, 7.8) 0.89 (0.15, 5.28) 0.32 (0.20, 0.52)a 0.18 (0.001, 27.32)
 HCIV 0.53 (0.07, 3.98) 0.31 (0.03, 2.88) 0.27 (0.16, 0.46)a 1.96 (0.01, 491.00)
 HCIII – – 0.21 (0.13, 0.33)a 2.59 (0.02, 331.66)
District
 Kampala 1.0 1.0
 Kayunga 0.17 (0.12, 0.24)a 0.02 (0.00, 3.54)
 Mpigi 0.20 (0.14, 0.28)a 0.36 (0.003, 38.44)
HSD
 Cases >100 1.0 1.0 1.0 1.0
 Cases <100 6.77 (0.81, 56.94) 6.71 (0.46, 97.96) 1.75 (1.33, 2.29)a 0.13 (0.001, 12.37)
Reason for visit
 ISS 1.0 1.0
 Infection 1.38 (0.44, 4.35) 1.72 (0.47, 6.35)
 General 3.42 (1.05, 11.12)a 4.38 (1.14, 16.84)a
History of admission
 Yes 2.76 (1.12, 6.84)a 2.92 (0.95, 9.02)
History of medical procedures
 Contact 1.0 1.0
 Inoculation 4.11 (0.45, 37.69) 50.76 (1.80, 1432.98)a
 Surgery 0.83 (0.06, 11.42) 2.48 (0.06, 99.30)
 Antibiotic use
  Yes 4.47 (1.15, 17.44)a 4.57 (0.90, 23.20) 0.79 (0.58, 1.07)a
 Use of gentamicin
  Yes 0.27 (0.05, 1.32) 0.17 (0.03, 0.95)a
 Use of ciprofloxacin
  Yes 1.52 (0.96, 2.40)a 5.71 (0.69, 47.01)
 Use of septrin
  Yes 4.33 (0.84, 22.47) 4.70 (0.33, 66.82) 0.53 (0.40, 0.71)a 1.92 (0.45, 8.23)
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our study was similar to findings among French Guiana 
Amerindians living in a very remote village [27]. There 
was significant variability among the three districts, one 
possible reason could be the nature of samples provided, 
when individuals visit outpatient clinics, the conveni-
ent specimen depends on the respective toilet habits of 
participants and possibly diet, however the nature of 
bathrooms at the clinic may not be conducive for a par-
ticipant to take much time there in. In Uganda commu-
nities with the wet and dry climate tend to have diets 
different from those of wet climate. The variation in sex 
distribution cannot be explained, neither is the presence 
of more elderly people in the rural district of Mpigi, this 
same district prescribed more ciprofloxacin, and gen-
tamicin, had higher admissions and surgeries too.
Susceptibility patterns
The resistance to antibacterial agents tested significantly 
varied across the three districts and was highest in the 
urban district of Kampala, save for cefoxitin where it 
was higher in the western rural district of Mpigi. Resist-
ance to piperacillin/tazobactam did not significantly vary 
across the districts but was highest in the eastern rural 
district of Kayunga. Our findings are consistent with pre-
vious studies that reported higher resistance in urban 
compared to rural areas [28, 29]. Resistance also varied 
within districts possibly reflecting differences in services 
offered by health care givers. It is also possible that seg-
regation in community activities where some are entirely 
agricultural based with sparse population lessens access 
to antibiotics. Populations having commercial activ-
ity and higher population density create opportunity for 
increased environmental density of antibiotic use and 
antibiotic resistant bacteria as a result of access to drug 
outlets and health facilities [28].
In this study, over 76 % of participants reported prior 
use of antimicrobial agents particularly septrin and peni-
cillins. The prevalence of HIV in Uganda necessitates use 
of antimicrobials for treatment of opportunistic infec-
tions, and the routine use of septrin prophylaxis against 
Pneumocystis jirovecii pneumonia. This could contributes 
to bacterial resistance [30, 31]. However in this study the 
use of septrin was protective against carriage MDR E. coli 
and K. pneumoniae. This finding requires focused stud-
ies to determine factors underlying this protection. Fur-
thermore, individuals with HIV/AIDs were significantly 
less likely to have E. coli and K. pneumoniae producing 
AmpC enzymes; this may be attributed to the decrease in 
infections attributed to use of basic care package (BCP), 
a patient managed, home based care system introduced 
since 2005 and is widely used [32]. It empowers HIV-pos-
itive people to avert opportunistic infections and expo-
sure to malaria transmitting mosquito among many other 
benefits; thus living a healthier life and preventing occur-
rence of diseases [33, 34]. This possibly keeps these indi-
viduals away from frequent exposure to health facilities, 
a factor likely to be contributing to carriage of AmpC in 
this study, and visiting drug outlets thus indirectly pro-
tecting them from exposure to AmpC-bearing Entero-
bacteriaceae. There was little use of third generation 
cephalosporins, β-lactamase inhibitors and cephamycins 
and yet resistance to the respective classes was detected 
among study participants. There is a possibility that use 
of antimicrobial agents to which bacteria are already 
resistant selects for further resistance and also co-selects 
resistant determinants that may be co linked to resistance 
of the respective drug in use.
The resistance to cefepime was noted to be higher 
than that of ceftriaxone, such resistance may be due to 
presence of oxacillinase enzymes like Oxa-30 and Oxa-
31, one of the derivatives of Oxa-1, that confers a spec-
trum sparing ceftazidime and cefotaxime and hydrolyses 
cefepime, but it has also been reported to be associated 
with alteration or loss of outer membrane porins [35, 
36]; these possibilities should be explored in subsequent 
studies.
The commonest MDR combination when associated 
with beta-lactamase enzymes determinants are likely to 
be selected for by use of respective antimicrobials, thus 
increasing the magnitude of beta-lactamases as postu-
lated elsewhere [37]. The health centers studied were 
assumed to serve over 70 % of the population. However 
there is inadequate laboratory diagnosis in most of the 
rural district areas often leaving resistance to go unde-
tected. Under these circumstances, empiric as opposed 
to targeted therapy prevails [38]. In the period of the 
study, visits to health facilities depended on availabil-
ity of medicines and stock outs were frequent consist-
ent with findings from previous studies [39]. When 
the antimicrobials were not present, clients may have 
resorted to drug outlets [40] where doses offered are 
suboptimal [10] and such exposure is an established 
driver of resistance. Frequent use of antimicrobial cre-
ates a pool of resistant commensal bacteria that contrib-
ute to general increase and dissemination of bacterial 
resistance worldwide [41]. In this setting, this is com-
pounded by the liberal use of antimicrobials by farmers 
[12]. Evidence from settings where antibacterial agents 
are accessed by prescription only, have shown that indi-
viduals prescribed an antibiotic in primary care develop 
bacterial resistance to the respective antibiotic, with 
effect being greatest in the month immediately after 
treatment but persistence may go on for over 12 months 
[42]. The high presence of septrin resistance in a setting 
where it is continuously used, may be explained by sev-
eral of the above factors.
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Factors associated with drug resistance
Multidrug resistance was common and factors such as 
age, level of health facility, location of health sub-district, 
district of residence, undergoing medical procedures and 
use of septrin were associated with multidrug resistance. 
However, only undergoing medical procedures associ-
ated with inoculation was an identified risk factor for car-
riage. Other factors yet to be identified contribute to the 
use of septrin within 3 months prior to visiting the clinics 
[cOR 0.53 (95 % CI 0.40, 0.71)] and district of residence 
whereby those from rural districts of Kayunga [cOR 0.17 
(95 % CI 0.11, 0.26)] and Mpigi [cOR 0.20 (95 % CI 0.13, 
0.32)] were protected from carriage of MDR flora com-
pared to those who reside in Kampala. Furthermore visit-
ing lower health centers like general hospital [cOR 0.32 
(95 % CI 0.20, 0.52)], HCIV [cOR 0.27 (95 % CI 0.16, 0.46] 
and HCIII [cOR 0.21 (95 % CI 0.13, 0.33)] compared to 
national referral hospital was protective of MDR carriage, 
the age group 15–44 was a risk factor for carriage of 
MDRisolates compared to participants  ≤15  years [cOR 
1.65 (95 % CI 1.22, 2.23)] and so were HSD of less than 
100 cases cOR 1.75 (95 % CI 1.33, 2.29).
Multidrug resistance was noted for over 60 % of ESBLs 
and 70 % AmpC bearing isolates; whereas no factor was 
independently associated with carriage of isolates pro-
ducing ESBLs, having used antibacterial agents during 
3 months prior to OPD visit may have combined with yet 
unknown factors to contribute to carriage of flora with 
the enzyme [cOR 4.47 (95 % CI 1.15, 17.44)]. Previously 
studies have reported that antibiotic exposure affects 
ESBL faecal carriage in the community [27].
The isolates with AmpC enzymes were independently 
associated with clinic visits for reasons other than infec-
tion or HIV/AIDs care [aOR 4.38 (95 % CI 1.14, 16.84)] 
while use of gentamicin was protective of such carriage 
[aOR 0.17 (95  % CI 0.03, 0.95)]. Participants with his-
tory of admission 3 months prior to admission were also 
likely to have carriage of isolates with AmpC enzymes 
[cOR =  2.76 (95  % CI 1.12, 6.84)]. Such findings high-
light the role played by direct interaction of clients with 
facility environment including health care givers. The 
association of hospital admission and care with AmpC 
and MDR isolates can be explained by the levels of over-
crowding in health facilities compounded by substand-
ard infection control practice in the study setting where 
hand hygiene is seen more as self-protection by health 
care givers as opposed to breaking the chain of transmis-
sion in the facility [43]. Such practice facilitate transmis-
sion of bacteria between clients and care givers [44]. This 
argument is strengthened by finding procedures associ-
ated with inoculation, where direct contact with health 
care providers is inevitable, as an independent risk 
factor.
Previous studies have pointed out the acquisition of 
AmpC enzyme bearing bacteria from health facilities. 
However the presence of these enzymes in the com-
munity following the introduction by those who visited 
health facilities is worrying [45] as they drive the use of 
Carbapenems for community-acquired infections [46] 
and are associated with poor outcome [46].The pres-
ence of MDR isolates in varied combination some cover-
ing over five different class drugs may be an indicator of 
evolving gene pools in flora from the study areas [47]. In 
this study age and sex were not independently associated 
with resistance.
Population exposure to antibiotics is related to ESBL 
community carriage rates [27]. However several studies 
in the past [28] and a recent one from Australia dem-
onstrated presence of resistance among individuals who 
have not taken antibiotics [48]. The presence of ESBL 
enzymes and associated MDR among individuals report-
ing to health centers without associated factors has been 
highlighted in other studies [49], and several sources for 
ESBL transmission in the community have been identi-
fied. For example ESBLs was detected from food of ani-
mal origin such as raw meat similar to faecal samples 
from hospitals in The Netherlands [50]. Extended-spec-
trum β-lactamase genes of E. coli was detected in chicken 
meat and humans, in the Netherlands [50]. Similarly in 
Uganda the resistance of E. coli isolates from faecal sam-
ples of chicken and pigs support the possibility of having 
resistance arising from the food chain [11]. Transmis-
sion of bacteria between human and animal sources has 
been reported from communities associating with wild 
life in Uganda [51] and in Portugal Enterobacteriaceae 
from health humans had resistance determinants simi-
lar to those from food producing animals [52]. Elsewhere 
in Kenya companion animals of Pastoralists were found 
to carry ESBls [53] and there is a possibility that similar 
scenarios of transmission of resistance take place in this 
setting.
The environment has been suggested to serve as a res-
ervoir for ESBL genes since isolates from varied sources 
are noted to be similar to those of humans [54]. A vari-
ety of factors such as community hygiene levels, people’s 
behavior, and antimicrobial resistance rates at commu-
nity level influence on transmission of resistant micro-
organisms. The transmission of commensal bacteria 
between individuals and antibiotic use occur all the time, 
this ensures selection of resistant bacteria in the commu-
nity [55]. Uganda being a low resource country, several 
factors are likely to be playing a role in the transmission 
of these resistance traits. The findings from rural central 
Uganda show that families with poor hygienic practices 
and environmental hygiene were significantly associated 
with having helminthes transmitted by oral faecal spread, 
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which would equally have transmission of resistant bac-
teria [56]. The sanitation standards in the urban areas 
are worsened by low levels of funding and supervision of 
sewage systems with frequent over flow of sewerage onto 
the surface [57]. On the other hand 70  % of the urban 
poor use shared latrines that quite often fail to serve the 
desired need of improved sanitation [58]. Furthermore 
there are unhygienic practice by food vendors in the 
region covering the study area [59]. In a low resource set-
ting purchase transaction involves use of bank notes and 
yet in the recent past contaminated bank notes have been 
identified as contributing to the transmission of ESBLs 
[60]. It is possible this occurs among individuals who may 
have no history of using antibacterial agents in this set-
ting too.
The level of resistance noted in this study has several 
implications. With minimal laboratory support for cul-
ture and sensitivity the chances of ineffective chemother-
apy, treatment failure and increased duration of hospital 
stay and death are likely to be rampant [61]. With pro-
longed illness, there is increased risk of spread of infec-
tion to other people with ultimate increase in costs of 
health care [62]. Uganda being a low income country, 
treatment of multidrug resistant bacteria necessitating 
the purchase of expensive last line antimicrobials is not 
easy to achieve in the public facilities [63, 64]. Thus these 
findings call for initiation of efforts to continuously col-
lect susceptibility data from both rural and urban areas to 
inform the planning of antibiotic policies and introduc-
ing antibiotic stewardship programs at all levels of health 
care delivery.
One limitation in this study was that we considered 
three colonies from all specimen with successful growth, 
instead of using antibiotic containing media to screen for 
antimicrobial resistance phenotypes. This could have led 
to missing some ESBLs. However, the study gives insight 
into the problem of MDR among ESBL negative bacteria. 
Use of client prescription notebooks and recall to give 
information about antimicrobials previously taken, may 
have left some antimicrobial use undetected. The use of 
specimen as opposed to rectal swabs affected the yield 
of flora. The findings from this study are based on cli-
ents attending outpatient clinics in the selected districts 
of central Uganda and may not be generalized to clients 
attending outpatient clinics throughout the country.
Conclusions
Antimicrobial resistance is wide-spread among E. coli 
and K. pneumoniae in clients attending outpatient clin-
ics in Kampala and rural districts of Uganda. This could 
complicate treatment options for community acquired 
infections caused by the enterobacteriaceae.
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